Sodium Fluoride F-18

The standard adult dose for Sodium Fluoride F-18 PET imaging typically ranges from 300 to 600 Megabecquerels (MBq), which is equivalent to 8 to 16 Millicuries (mCi). The exact dose is calculated by the nuclear medicine physician based on the patient's body weight, the specific PET scanner being used, and the clinical indication for the scan. For most adults, a dose of 370 MBq (10 mCi) is standard. The injection is administered as a slow intravenous bolus.

Sodium Fluoride F-18 is used in pediatric patients, but the dosage must be strictly adjusted based on body weight to minimize radiation exposure. The recommended pediatric dose is typically 2.1 MBq per kilogram (0.057 mCi/kg) of body weight. Healthcare providers follow the 'As Low As Reasonably Achievable' (ALARA) principle to ensure children receive the minimum amount of radiation necessary to obtain a high-quality diagnostic image. The minimum dose is usually around 19 MBq (0.5 mCi).

Renal Impairment

Patients with impaired kidney function (renal insufficiency) may require special consideration. Since the drug is cleared through the urine, poor kidney function can lead to slower clearance of the radioactivity from the body, potentially increasing the radiation dose to the bladder and kidneys. While the injected dose might not always be reduced, the patient may be instructed to increase fluid intake significantly to help flush the agent out.

Hepatic Impairment

No dosage adjustments are typically required for patients with liver disease, as Sodium Fluoride F-18 is not metabolized by the liver and does not rely on hepatic pathways for excretion.

Elderly Patients

In elderly patients, the primary concern is often underlying renal function. Healthcare providers will assess the glomerular filtration rate (GFR) to ensure the patient can adequately eliminate the radiopharmaceutical after the scan is complete.

Sodium Fluoride F-18 is administered exclusively by a healthcare professional via intravenous injection.

• Preparation: You do not usually need to fast before the scan. However, you should be well-hydrated. Your doctor may ask you to drink several glasses of water before you arrive.
• The Procedure: After the injection, you will wait approximately 30 to 60 minutes for the fluoride to be absorbed by your bones. During this time, you may be asked to rest quietly.
• Post-Injection: You will be asked to urinate immediately before the scan starts to empty your bladder, which helps the doctor see the pelvic bones more clearly and reduces radiation exposure to the bladder.
• Storage: This drug is stored at the medical facility in lead-shielded containers at room temperature and is never handled by the patient.

Since Sodium Fluoride F-18 is administered for a scheduled imaging procedure by a professional, a 'missed dose' in the traditional sense does not occur. If you miss your appointment, the dose prepared for you will likely expire due to its short 110-minute half-life, and a new dose will need to be ordered for a rescheduled time.

An overdose of Sodium Fluoride F-18 is extremely rare because the dose is precisely calculated and measured before administration. In the event of an accidental administration of an excessive dose, the primary risk is increased radiation exposure. The management strategy involves 'forced diuresis'—encouraging the patient to drink large amounts of fluids and urinate frequently to speed up the removal of the radioactive material from the body.

> Important: Follow your healthcare provider's dosing and preparation instructions exactly. Do not attempt to adjust your appointment time without notifying the nuclear medicine department, as the medication is time-sensitive.

Sodium Fluoride F-18 is generally very well tolerated, and most patients do not experience any noticeable side effects from the drug itself. Because it is a diagnostic tracer used in very small (microgram) quantities, it does not have the same side effect profile as therapeutic medications. However, some patients may experience:

• Injection Site Reactions: A brief sensation of coldness, stinging, or minor bruising at the site where the needle was inserted.
• Temporary Metallic Taste: A small number of patients report a brief metallic or unusual taste in the mouth immediately following the injection.

• Headache: Some patients report a mild headache following the procedure, though it is often unclear if this is due to the drug, the stress of the imaging environment, or slight dehydration.
• Nausea: Mild, transient nausea has been reported in fewer than 2% of clinical trial participants.

• Dizziness: Feeling lightheaded shortly after the injection.
• Fever or Chills: A very rare systemic response to the injection.
• Skin Rash: Mild itching or redness (hives) that typically resolves without intervention.

While extremely rare, serious reactions can occur. You should inform the medical staff immediately if you experience any of the following during or after the injection:

> Warning: Stop the procedure and call for help if you experience:

• Anaphylaxis (Severe Allergic Reaction): Symptoms include swelling of the face, lips, or throat, difficulty breathing, or a rapid drop in blood pressure.
• Severe Hives: Widespread, itchy red welts on the skin.
• Chest Pain: Any discomfort in the chest area during the administration.

There are no known long-term 'pharmacological' side effects of Sodium Fluoride F-18, as the drug is completely gone from the body within 24 hours. The primary long-term consideration is cumulative radiation exposure. Every radiopharmaceutical contributes to a person's lifetime radiation dose. While a single NaF F-18 scan is within the safety limits for diagnostic procedures, repeated scans over many years can theoretically increase the risk of cancer. However, the diagnostic benefit of identifying bone metastases usually far outweighs this theoretical risk.

There are currently no FDA black box warnings for Sodium Fluoride F-18. It is considered a safe and effective diagnostic tool when used according to established protocols.

Report any unusual symptoms, even if they seem minor, to your healthcare provider or the nuclear medicine technologist during your scan. They are trained to manage any immediate reactions to the radiopharmaceutical.

Sodium Fluoride F-18 is a radioactive material and must be handled with extreme care by authorized personnel only. The primary safety concern for the patient is the radiation dose to the internal organs, particularly the bladder. To minimize this risk, patients must be well-hydrated before the procedure and must urinate as often as possible for several hours after the injection. This helps to 'flush' the radioactive fluoride out of the urinary system, reducing the time the bladder wall is exposed to radiation.

No FDA black box warnings for Sodium Fluoride F-18.

• Allergic Reactions: While rare, hypersensitivity reactions (allergic reactions) can occur. Patients with a history of allergies to fluoride or other radiopharmaceuticals should inform their doctor before the scan. Facilities where NaF F-18 is administered are equipped with emergency medications like epinephrine to treat anaphylaxis.
• Radiation Risk: Sodium Fluoride F-18 contributes to your total radiation exposure. This is particularly important for patients who undergo frequent medical imaging. Healthcare providers must ensure that the benefit of the scan justifies the radiation dose.
• Renal Function: Because the drug is excreted through the kidneys, patients with severe kidney disease may have poor image quality and delayed clearance of the radiation. Doctors will evaluate kidney function before proceeding.
• Bone Flare Phenomenon: In patients being treated for cancer, a 'flare' can occur where bone spots appear brighter or more numerous on a scan shortly after starting a new treatment (like chemotherapy or hormone therapy). This does not always mean the cancer is getting worse; it can be a sign that the bone is healing. This is a diagnostic precaution rather than a physical danger.

There are no specific long-term lab tests required for patients receiving a single dose of Sodium Fluoride F-18. However, during the procedure, the technologist will monitor the injection site for signs of 'extravasation' (where the drug leaks out of the vein into the surrounding tissue). If you have pre-existing kidney disease, your doctor may monitor your serum creatinine levels before the scan.

Sodium Fluoride F-18 does not cause drowsiness or impairment of cognitive function. You should be able to drive yourself home after the scan unless you have received a sedative for claustrophobia during the PET scan itself. Always check with your doctor if you feel lightheaded after the procedure.

There are no known direct interactions between alcohol and Sodium Fluoride F-18. However, alcohol can cause dehydration. Because hydration is critical for clearing the radiation from your body, it is recommended to avoid alcohol for 24 hours before and after the scan.

As this is a one-time diagnostic injection, there are no tapering requirements or withdrawal syndromes associated with Sodium Fluoride F-18.

> Important: Discuss all your medical conditions, especially pregnancy or kidney issues, with your healthcare provider before starting Sodium Fluoride F-18.

There are no medications that are strictly contraindicated (forbidden) for use with Sodium Fluoride F-18. Because it is a diagnostic tracer used in minute quantities, it does not interfere with the chemical action of other drugs. However, certain drugs may interfere with the accuracy of the test results.

• Bisphosphonates (e.g., Alendronate, Zoledronic Acid): These drugs are used to treat osteoporosis and bone metastases. They work by binding to the same hydroxyapatite sites as Sodium Fluoride F-18. If a patient is taking high doses of bisphosphonates, it may reduce the uptake of the F-18 tracer, potentially leading to a 'false negative' result where bone lesions are not as visible. Doctors may recommend timing the scan specifically in relation to the bisphosphonate dose.
• Denosumab (Prolia, Xgeva): Similar to bisphosphonates, this medication alters bone turnover. It can significantly decrease the 'background' uptake of fluoride in the bones, which might change how the scan is interpreted.

• Corticosteroids (e.g., Prednisone): Long-term use of steroids can affect bone metabolism and may slightly alter the appearance of the skeleton on a PET scan. This is a pharmacodynamic interaction where the drug changes the target (the bone) rather than the tracer itself.
• Chemotherapy Agents: Certain chemotherapy drugs can cause 'bone marrow activation' or 'flare reactions.' This can cause the PET scan to show increased activity in the bones that could be mistaken for cancer progression. It is vital that the nuclear medicine physician knows the timing of your last chemotherapy session.

There are no known food interactions with Sodium Fluoride F-18. Unlike some other PET tracers (like FDG which requires fasting to manage glucose levels), Sodium Fluoride F-18 uptake is not affected by blood sugar or recent meals. However, staying hydrated with water is essential.

• Calcium and Vitamin D Supplements: While normal use of these supplements does not typically interfere with the scan, extremely high levels of calcium in the blood (hypercalcemia) can theoretically affect bone turnover rates.
• Fluoride Supplements: If a patient is taking high-dose prescription fluoride supplements for dental or bone health, this could theoretically compete with the F-18 ions for binding sites in the bone, though this is rarely clinically significant.

Sodium Fluoride F-18 does not interfere with standard blood chemistry or hematology tests. However, the presence of radioactivity in the blood and urine for the first 12-24 hours after the scan could potentially interfere with certain highly sensitive radioimmunoassays (specialized lab tests that also use radioactive markers). If you need blood work done, it is best to wait 24 hours after your PET scan.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your bones.

• Hypersensitivity: Sodium Fluoride F-18 is absolutely contraindicated in patients with a known, documented severe allergy to Sodium Fluoride or any of the components in the injection. Anaphylaxis is a life-threatening emergency, and the drug must never be administered if a previous reaction has occurred.
• Pregnancy (Confirmed): While not always an 'absolute' contraindication in life-threatening emergencies, it is generally avoided. Radiation exposure to a developing fetus can cause birth defects or increased cancer risk for the child. Unless the benefit to the mother's life significantly outweighs the risk to the fetus, the scan should be postponed.

• Severe Renal Failure: In patients with anuria (not producing urine) or severe kidney disease, the tracer cannot be cleared from the body. This results in a very high radiation dose to the patient and poor image quality, as the radioactivity remains in the blood rather than clearing to show the bones clearly. A risk-benefit analysis is required.
• Breastfeeding: This is a relative contraindication. The radioactive fluoride can be excreted in breast milk. Mothers are usually advised to stop breastfeeding and discard milk for at least 12 to 24 hours after the injection to ensure the infant is not exposed to radiation.
• Recent Bone Surgery or Trauma: Recent fractures or surgeries will show intense uptake of the tracer. While not a safety contraindication, it can make the scan difficult to interpret if the doctor is looking for cancer near the site of a recent injury.

There is no known cross-sensitivity between Sodium Fluoride F-18 and iodinated contrast media (used in CT scans) or gadolinium-based contrast (used in MRI). If you are allergic to CT or MRI dye, you can usually still safely receive a Sodium Fluoride F-18 injection.

> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and pregnancy status, before prescribing Sodium Fluoride F-18.

Sodium Fluoride F-18 is classified as FDA Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women. However, it is known that radioactive substances can cross the placenta and be absorbed by the fetus. The fetal skeleton is rapidly developing, meaning it would take up a significant amount of the radioactive fluoride. This poses a risk of radiation-induced injury or future malignancy. If a scan is absolutely necessary, the lowest possible dose should be used, and the patient should be informed of the risks.

It is not known exactly how much Sodium Fluoride F-18 is excreted in human breast milk, but many radiopharmaceuticals are present in milk. To minimize risk to the nursing infant, a lactating woman should pump and discard breast milk for at least 12 to 24 hours after receiving the injection. During this time, the infant should be fed with previously expressed milk or formula.

Sodium Fluoride F-18 is used in children to evaluate bone lesions. However, interpretation must be done by a specialist, as children have 'active growth plates' (epiphyseal plates) that naturally take up large amounts of fluoride. This is normal for a growing child but can look like an abnormality to an untrained eye. Dosing must be strictly weight-based to limit radiation exposure.

In clinical studies, no overall differences in safety or effectiveness were observed between elderly patients (65 and over) and younger patients. The main concern in this population is the higher prevalence of decreased renal function. Because the drug is cleared renally, elderly patients should be monitored for adequate hydration to ensure the tracer is eliminated promptly.

Patients with a reduced Glomerular Filtration Rate (GFR) will experience slower clearance of the tracer from the blood. This can lead to 'blurry' images because the background radioactivity remains high. Furthermore, it increases the radiation dose to the kidneys and bladder. In patients with GFR < 30 mL/min, the diagnostic utility of the scan may be limited.

Since the liver is not involved in the uptake or excretion of Sodium Fluoride F-18, no specific precautions or dose adjustments are required for patients with liver cirrhosis or hepatic failure.

> Important: Special populations require individualized medical assessment to balance the diagnostic benefits against the risks of radiation exposure.

Sodium Fluoride F-18 acts as a bone-seeking radiopharmaceutical. The mechanism is based on simple ion exchange. The skeletal hydroxyapatite crystal $[Ca_{10}(PO_4)_6(OH)_2]$ has hydroxyl groups ($OH^-$) that can be replaced. The Fluoride F-18 ion ($^{18}F^-$) has a similar size and charge to the hydroxyl ion. When the tracer reaches the bone surface, the $^{18}F^-$ replaces the $OH^-$ to form $^{18}F$-labeled fluorapatite. This process occurs preferentially in areas with high blood flow and high bone turnover (osteoblastic activity).

Sodium Fluoride F-18 does not produce a measurable physiological effect at the doses used for imaging. It does not stimulate or inhibit any receptors or enzymes. The 'effect' is purely the emission of radiation for detection. The time to onset for bone visualization is roughly 30-60 minutes, and the 'duration of effect' is limited by the physical decay of the isotope (half-life of 110 minutes).

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | Negligible |

| Physical Half-life | 109.7 minutes |

| Tmax (Bone Uptake) | 45 - 60 minutes |

| Metabolism | None (Physical decay to Oxygen-18) |

| Excretion | Renal (20% - 50% in first 3 hours) |

The molecular formula is $Na^{18}F$. It has a molecular weight of approximately 41.0 (depending on the isotope). It is highly soluble in water. The Fluorine-18 isotope is produced in a cyclotron by proton irradiation of Oxygen-18 enriched water. It decays by positron ($eta^+$) emission to stable Oxygen-18, with a maximum positron energy of 0.633 MeV.

Sodium Fluoride F-18 is classified as a Radioactive Diagnostic Agent and a Radiopharmaceutical. It is part of a group of agents used in Positron Emission Tomography (PET). Other drugs in this broad category include Fludeoxyglucose F-18 (FDG) and Gallium Ga-68 Dotatate, though these target different biological processes (glucose metabolism and somatostatin receptors, respectively).